Arrowhead Pharmaceuticals
The Specification Lead serves as the quality owner for the specification lifecycle of Arrowhead's product portfolio, managing the creation, review, and approval of specifications from early clinical development through commercial supply. This role ensures acceptance criteria are phase-appropriate, scientifically justified, and aligned with regulatory and compendial requirements. The position involves collaborating with cross-functional teams including Analytical Development, Quality Control, CMC, and Regulatory Affairs to maintain inspection readiness and drive specification program metrics.
Headquarters
Pasadena, California, United States
Company Size
501-1000 employees
Founded
2004
Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops, and delivers RNA interference (RNAi)-based therapeutics to silence disease-causing genes. Using proprietary targeted delivery platforms that enable focused, durable gene knockdown, Arrowhead advances programs across liver and extra‑hepatic indications including cardiometabolic, pulmonary, viral, and rare diseases. The company progresses multiple clinical and preclinical candidates and collaborates with partners to translate RNAi science into new therapies that aim to change how diseases are treated.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Arrowhead Pharmaceuticals.
Sr. Scientific Specialist - Specification Generation
Alcami Corporation
Associate Director US Regulatory Affairs CMC
C0003153479P
Associate Director US Regulatory Affairs CMC
C0003153479P
Associate Director, Regulatory Affairs - CMC
PTC Therapeutics
Associate Director, Regulatory Affairs – CMC
PTC Therapeutics
Director, Regulatory CMC
Dyne Therapeutics